Page 75 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: MD Anderson Cancer Center HOUSTON Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer. The results, presented today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, showcase the researchers ongoing efforts to advance clinical studies and expand potential indications of approved drugs to develop a platform for more effective treatments and to improve patient outcomes. FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers (Abstract CT011)

United statesVivek subbiahNakiad spencerEli lillyTranslational research to advance therapeuticsAmerican association for cancer researchInstitute for applied cancer scienceUniversity of texas md anderson cancer centerDrug administrationCancer centerAmerican associationCancer researchAnnual meetingInvestigational cancerTherapeutics discoveryTranslational research